Key result
During 2017, several landmark studies provided new evidence for ASCVD risk reduction through lipid-lowering, systemic inflammation reduction, and antithrombotic therapy.
A 2017 year-in-review summarizing landmark trials in cardiovascular prevention, highlighting the emergence of novel lipid-lowering, anti-inflammatory, and antithrombotic therapies.
Alerts clinicians to 2017 ASCVD prevention advances; leaves open optimal integration and durability in practice.
During 2017 several landmark studies have been published that have practical implications for atherosclerotic cardiovascular disease (ASCVD) prevention and risk factor control, such as lipids and lipoproteins, inflammation, diabetes, hypertension, and healthy lifestyle. We use the term 'ASCVD' where relevant to simplify the reading of this article for the non-specialist, although the exact definition as ASCVD differ slightly from study to study. However, in sections where ASCVD clearly is not the relevant endpoint (e.g. in hypertension research) we do not use 'ASCVD', but instead of use other words to describe endpoints. All relevant trials have been performed on a background of optimal medical therapy, such as described in the European Society of Cardiology(ESC)/European Atherosclerosis Society(EAS) guidelines on ASCVD prevention and management of dyslipidaemia for lipid-lowering. 1,2 For example, important new evidence for additional risk reduction relates to lipid-lowering [proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition, 3 cholesteryl ester transfer protein (CETP) inhibition 4 ] to the reduction of systemic inflammation (interleukin-1b inhibition 5 ) and to antithrombotic therapy (low-dose factor Xa antagonism 6 ). Since these novel treatments have not yet been tested in combination and because of the practical and economic limitations, an important challenge for the years to come is patient selection. Also, the benefit to risk dimension of any new therapeutic agent needs to be considered. This review article is intended to provide the practicing physician with the information needed to identify patients in secondary prevention that may benefit the most from additional novel treatments (Figure Use and accessibility of novel treatments will depend critically on whether patients live in high income, upper middle-income or lower middle-income countries, as levels of cardiovascular risk factors, cardiovascular mortality rates, and thus the prevention potential differ between such countries.
No takes yet. Share an insight, caveat, or question.
Nordestgaard et al. (2017) conducted a review in Atherosclerotic cardiovascular disease (ASCVD) prevention. Novel treatments for ASCVD prevention was evaluated. During 2017, several landmark studies provided new evidence for ASCVD risk reduction through lipid-lowering, systemic inflammation reduction, and antithrombotic therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: